Gastroenterology
Digestive system clinical trials
Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We’re tracking 7,903 recruiting studies in this area right now.
By phase
- Not applicable4,926
- Phase 21,187
- Phase 1582
- Phase 3466
- Phase 1/Phase 2395
- Phase 4236
- Phase 2/Phase 3111
Top conditions
- Colorectal Cancer493
- Gastric Cancer297
- Pancreatic Cancer292
- Hepatocellular Carcinoma284
- Esophageal Cancer191
- Rectal Cancer176
- Breast Cancer147
- Crohn Disease144
- Ulcerative Colitis141
- Colon Cancer115
- Inflammatory Bowel Diseases108
- Hepatocellular Carcinoma (HCC)106
- Liver Cancer101
- Lung Cancer98
- Pancreas Cancer94
- Esophageal Squamous Cell Carcinoma88
- Ovarian Cancer88
- Cystic Fibrosis78
Leading sponsors
- Fudan University104
- Sun Yat-sen University91
- Mayo Clinic74
- Chinese University of Hong Kong60
- M.D. Anderson Cancer Center58
- Second Affiliated Hospital, School of Medicine, Zhejiang University57
- Assistance Publique - Hôpitaux de Paris55
- Sixth Affiliated Hospital, Sun Yat-sen University50
- National Taiwan University Hospital49
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences48
Where studies are running
- California462
- Arizona177
- Texas149
- Florida135
- Massachusetts127
- New York123
- Alabama122
- Maryland86
- Ohio80
- Pennsylvania72
Recruiting studies7,903 total
- NCT07100405Recruiting
TACE plus Immunotherapy for Advanced Liver Cancer
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07101237Recruiting
Precision diagnosis and treatment study for liver cancer
This study aims to improve how doctors diagnose and treat liver cancer by combining advanced imaging tests and genetic analysis. It may help in choosing the most effective treatment for each person.
BeijingAges 18–70 - NCT07102368Recruiting
Study of guselkumab for inflammatory bowel disease in Germany
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
BerlinAges 18 years+ - NCT07102901RecruitingPhase 2
Study of SHR2554 with other therapies for gastric or junction cancer
This trial tests a new drug, SHR2554, combined with other anticancer treatments for advanced stomach or gastroesophageal junction cancer. It aims to see if the combination is safe and effective. You may qualify if you have measurable disease and are generally in good health.
Harbin, HeilongjiangAges 18–75 - NCT07104214Recruiting
Predicting stomach retention risk before sedated endoscopy
This study is building a tool to predict if a patient's stomach will empty normally before a sedated upper endoscopy (gastroscopy). It tests risk factors that help doctors plan safer procedures.
Hangzhou, ZhejiangAges 18 years+ - NCT07105631Recruiting
Study of cediranib and immunotherapy in advanced colorectal cancer
This study looks at how patients with a certain type of advanced colorectal cancer (MSS-type) feel and do during treatment with a combo of cediranib and immunotherapy. It aims to learn about side effects, quality of life, and how well the treatment works in everyday practice.
Chengdu, SichuanAges 18 years+ - NCT07105748RecruitingPhase 2
HAIC plus Camrelizumab and Rivoceranib for advanced mixed liver-bile duct cancer
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07106827RecruitingPhase 1
Study of a new drug for advanced or resistant solid tumors
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
Chengdu, SichuanAges 18 years+ - NCT07106814RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy (Meta10-TIL) made from your own immune cells that were trained to attack cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including cervical, liver, lung, breast, ovarian, head and neck, or colorectal cancer.
Hefei, AnhuiAges 19–70 - NCT07106892RecruitingPhase 2
Testing HLX43 for advanced colorectal cancer
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
BeijingAges 3 weeks–2 months - NCT07107750RecruitingPhase 1
New drug combo for untreated advanced bile duct cancer
This trial tests a new targeted drug (emavusertib) combined with standard chemotherapy and immunotherapy for people with advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination is safe and effective.
St Louis, MissouriAges 18 years+ - NCT07108075Recruiting
Testing metformin and carvedilol for cirrhosis with variceal bleeding
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
New Delhi, National Capital Territory of DelhiAges 18–75 - NCT07108127RecruitingPhase 2
Targeted drugs plus chemo for HER2-positive rectal cancer
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
BeijingAges 18 years+ - NCT07108348Recruiting
ADAR1 levels in rectal cancer
This study looks at a protein called ADAR1 in rectal cancer tissue. It aims to see how ADAR1 levels might be related to the cancer and help doctors understand the disease better.
Konya, MeramAges 18–90 - NCT07108517Recruiting
Post-traumatic growth program for cancer survivors in Greece
This trial tests a guided program to help people with breast, colorectal, or head and neck cancer find personal growth after finishing chemotherapy. It is for those who have completed their planned treatment within the last 5 years and are not currently in other psychological care.
ThessalonikiAges 18–80 - NCT07108855RecruitingPhase 1/Phase 2
Green dye to guide early cancer removal
This trial tests whether a special dye (indocyanine green) given through a vein can help doctors see the exact edges and depth of early-stage esophageal or stomach cancer during a minimally invasive procedure to remove it. If you are scheduled for this procedure, the dye may help the surgeon remove the cancer more precisely.
Groningen, Provincie GroningenAges 18 years+ - NCT07109180Recruiting
Robot vs. open surgery for chronic pancreatitis pain
This study compares robot-assisted vs. open surgery for treating chronic pancreatitis pain. It aims to see which approach works better for people with a dilated pancreatic duct who need relief from severe symptoms.
AmsterdamAges 18 years+ - NCT07110571RecruitingPhase 2
Combination therapy study for untreated stomach or GEJ cancer
This trial tests a combination of adebrelimab (an immunotherapy) with either two other experimental drugs (SHR-A1811 or SHR-A1904) plus chemotherapy, or another drug (SHR-8068), as a first treatment for gastric or gastroesophageal junction adenocarcinoma. It aims to find if these combos work better than standard care.
Shijiazhuang, HebeiAges 18–70 - NCT07111221Recruiting
Reducing bleeding risk before liver transplant
This trial tests a procedure to lower blood loss during liver transplant for patients with high blood pressure in the liver. It may help those who have had a previous transplant, abdominal surgery, or certain complications of liver disease.
WarsawAges 18 years+ - NCT07111715Recruiting
AI vs. standard reading for suspected Crohn disease
This study tests whether an artificial intelligence (AI) system can help doctors find signs of Crohn's disease better than standard reading of capsule endoscopy images. It is for people who have symptoms that might be Crohn's but whose colonoscopy didn't clearly show the problem.
BresciaAges 18–75 - NCT07112690Recruiting
Nerve block for radiation pain during anal cancer treatment
This study tests a nerve block procedure (ganglion impar neurolysis) to reduce severe pain caused by radiation therapy for anal or perianal skin cancer. It may help you manage pain while you continue your cancer treatment.
Atlanta, GeorgiaAges 18 years+ - NCT07113275RecruitingPhase 3
Short versus long radiation schedule for advanced rectal cancer
This study compares two different schedules of radiation (a short course versus a longer course) followed by standard chemotherapy and immunotherapy for advanced rectal cancer. It aims to see which approach works best to shrink the tumor before surgery.
Wuhan, HubeiAges 18–75 - NCT07113522RecruitingPhase 2
Study of new therapies for Crohn's and colitis
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
Birmingham, AlabamaAges 18–80 - NCT07114159Recruiting
Sacral nerve stimulation for ulcerative colitis
This trial tests if sacral nerve stimulation can safely help people with ulcerative colitis that hasn't improved with standard treatments. It aims to see if this approach can reduce symptoms and improve quality of life.
Xi'an, ShaanxiAges 18–65
Common questions
- How many digestive system clinical trials are recruiting?
- Clin2 is tracking 7,903 recruiting gastroenterology studies from the U.S. registry right now, out of 12,451 we cover in this area in total.
- What does “Digestive system” cover here?
- Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We group each study into digestive system based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a digestive system trial near me?
- Use the search to filter digestive system studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.